Modulation of tumor-host interactions, angiogenesis, and tumor growth by tissue inhibitor of metalloproteinase 2 via a novel mechanism

Cancer Research

Volumn 64, Issue 13, 2004, Pages 4481-4486

  Feldman, Andrew L ^a   Stetler Stevenson, William G ^a   Costouros, Nick G ^a   Knezevic, Vladimir ^b   Baibakov, Galina ^b   Alexander Jr , H Richard ^a   Lorang, Dominique ^a   Hewitt, Stephen M ^a   Seo, Dong Wan ^a   Miller, Marshall S ^a   O'Connor, Sarah ^a   Libutti, Steven K ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b 20/20 GeneSystems Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MATRIX METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE 1; PHOSPHATASE; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SOLID TUMOR; UPREGULATION; VALIDATION PROCESS;

ANIMALS; CELL CYCLE PROTEINS; CELL DIVISION; COLONIC NEOPLASMS; ENZYME INDUCTION; FEMALE; GENE EXPRESSION PROFILING; IMMEDIATE-EARLY PROTEINS; MICE; MICE, INBRED C57BL; MITOGEN-ACTIVATED PROTEIN KINASES; NEOVASCULARIZATION, PATHOLOGIC; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHOPROTEIN PHOSPHATASE; PHOSPHORYLATION; PROTEIN-TYROSINE-PHOSPHATASE; RETROVIRIDAE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TRANSDUCTION, GENETIC;

EID: 3042739623     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-03-2929     Document Type: Article

References (24)

1. Hoegy SE, Oh HR, Corcoran ML, Stetler-Stevenson WG. Tissue inhibitor of metalloproteinases-2 (TIMP-2) suppresses TKR-growth factor signaling independent of metalloproteinase inhibition. J Biol Chem 2001;276:3203-14.
2. Stetler-Stevenson WG. Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention. J Clin Investig 1999;103:1237-41.
3. Feldman AL, Libutti SK. Antiangiogenesis. In: Lotze MT, editor. The cytokine handbook. London: Elsevier; 2003. p. 1279-95.
4. Liotta LA, Kohn EC. The microenvironment of the tumour-host interface. Nature (Lond.) 2001;411:375-9.
5. Zucker S, Cao J, Chen WT. Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. Oncogene 2000;19:6642-50.
6. Seo DW, Li H, Guedez L, et al. TIMP-2 mediated inhibition of angiogenesis: an MMP-independent mechanism. Cell 2003;114:171-80.
7. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst (Bethesda) 1990;82:4-6.
8. Holmgren L, O'Reilly MS, Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1995;1:149-53.
9. Feldman AL, Alexander HR, Hewitt SM, et al. Effect of retroviral endostatin gene transfer on subcutaneous and intraperitoneal growth of murine tumors. J Natl Cancer Inst (Bethesda) 2001;93:1014-20.
10. Feldman AL, Costouros NG, Wang E, et al. Advantages of mRNA amplification for microarray analysis. Biotechniques 2002;33:906-12, 914.
11. Englert CR, Baibakov GV, Emmert-Buck MR. Layered expression scanning: rapid molecular profiling of tumor samples, Cancer Res 2000;60:1526-30.
12. Kisker O, Becker CM, Prox D, et al. Continuous administration of endostatin by intraperitoneally implanted osmotic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model. Cancer Res 2001;61:7669-74.
13. Hajitou A, Sounni NE, Devy L, et al. Down-regulation of vascular endothelial growth factor by tissue inhibitor of metalloproteinase-2: effect on in vivo mammary tumor growth and angiogenesis. Cancer Res 2001;61:3450-7.
14. Schnaper HW, Grant DS, Stetler-Stevenson WG, et al. Type IV collagenase(s) and TIMPs modulate endothelial cell morphogenesis in vitro. J Cell Physiol 1993;156: 235-46.
15. Murphy AN, Unsworth EJ, Stetler-Stevenson WG. Tissue inhibitor of metalloproteinases-2 inhibits bFGF-induced human microvascular endothelial cell proliferation. J Cell Physiol 1993;157:351-8.
16. Keyse SM. Protein phosphatases and the regulation of MAP kinase activity. Semin Cell Dev Biol 1998;9:143-52.
17. Kiemer AK, Weber NC, Furst R, Bildner N, Kulhanek-Heinze S, Vollmar AM. Inhibition of p38 MAPK activation via induction of MKP-1: atrial natriuretic peptide reduces TNF-alpha-induced actin polymerization and endothelial permeability. Circ Res 2002;90:874-81.
18. Lee OH, Bae SK, Bae MH, et al. Identification of angiogenic properties of insulin-like growth factor II in in vitro angiogenesis models. Br J Cancer 2000;82:385-91.
19. Rousseau S, Houle F, Landry J, Huot J. p38 MAP kinase activation by vascular endothelial growth factor mediates actin reorganization and cell migration in human endothelial cells. Oncogene 1997;15:2169-77.
20. Tanaka K, Abe M, Sato Y. Roles of extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinase in the signal transduction of basic fibroblast growth factor in endothelial cells during angiogenesis. Jpn J Cancer Res 1999;90:647-54.
21. Jackson JR, Bolognese B, Hillegass L, et al. Pharmacological effects of SB 220025, a selective inhibitor of P38 mitogen-activated protein kinase, in angiogenesis and chronic inflammatory disease models. J Pharmacol Exp Ther 1998;284:687-92.
22. , Charles CH, Sun H, Lau LF, Tonks NK. The growth factor-inducible immediate-early gene 3CH134 encodes a protein-tyrosine-phosphatase. Proc Natl Acad Sci USA 1993;90:5292-6.
23. Lin WW, Hsu YW. Cycloheximide-induced cPLA(2) activation is via the MKP-1 down-regulation and ERK activation. Cell Signal 2000;12:457-61.
24. Seta KA, Kim R, Kim HW, Millhom DE, Beitner-Johnson D. Hypoxia-induced regulation of MAPK phosphatase-1 as identified by subtractive suppression hybridization and cDNA microarray analysis. J Biol Chem 2001;276:44405-12.